Brief: GT Biopharma Announces First Patient Dosed In Phase 1 Trial Of GTB-5550, A B7-H3-Targeted Natural Killer (NK) Cell Engager For Solid Tumors
14/05/2026 13:38
May 14 (Reuters) - GT Biopharma Inc GTBP.O: GT BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL OF GTB-5550, A B7-H3-TARGETED NATURAL KILLER (NK) CELL ENGAGER FOR SOLID TUMORS GT BIOPHARMA INC - COMPANY TO PROVIDE TRIAL UPDATES IN SECOND HALF 2026 Source text: ID:nGNX3QF13J Further company coverage: GTBP.O ((Reuters.Briefs@thomsonreuters.com;))